Skip to main content

Table 2 Baseline and on follow up clinical characteristics for cohort of patients on ART for a least 6 months at JUSH, September 2012 to July 2014

From: Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: a two years retrospective cohort study

Clinical characteristics TDF group no (%) AZT group no (%) P value
Baseline CD4+ count
 <200 92 (65.7) 74 (53.9) 0.029*
 ≥200 48 (34.3) 66 (47.1)  
 Mean (SD) 164.64 (83.36) 175.21 (89.14) 0.307**
Baseline WHO clinical stage
 I 32 (22.9) 36 (25.7)  
 II 46 (32.9) 47 (33.6) 0.928
 III 47 (33.6) 43 (30.7)  
 IV 15 (10.6) 14 (10)  
Baseline functional status
 W 110 (78.6) 79 (56.4)  
 A 24 (17.1) 56 (40.0) 0.000*
 B 6 (4.3) 5 (3.6)  
TB Treatment
 No 120 (84.7) 113 (87.9) 0.773
 Yes 20 (15.3) 17 (12.1)  
Prophylaxis
 CPT+ INH 37 (26.4) 30 (21.5)  
 CPT alone 86 (61.4) 99 (70.7) 0.231
 Neither 17 (12.2) 11 (7.8)  
  1. * Statistically significant at P value 0.05 cut off point
  2. ** T test